ISRCTN18660493已完成1 期
A phase I study to assess safety and tolerability and neutralising activity of CL184 in healthy volunteers
Crucell Holland BV (The Netherlands)0 个研究点目标入组 57 人开始时间: 2007年5月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 57
研究概览
简要总结
2008 Results article in https://pubmed.ncbi.nlm.nih.gov/18804136/ (added 01/09/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Healthy volunteers between 19 and 55 years of age
- •2. No previous treatment with rabies vaccine
- •3. Body Mass Index (BMI) between 20 and 28 kg/m^2
排除标准
- •1. Pregnant women, women planning to become pregnant and breastfeeding women
- •2. A history of or currently active clinically significant cardiac (including clinically significant abnormalities on Electrocardiogram [ECG] according to Principal Investigator [PI]), pulmonary, gastrointestinal, hepatic, renal, pancreatic, or neurological disease
研究者
相似试验
已完成
1 期
A phase Ib study to assess safety and tolerability and neutralising activity of CL184 in healthy volunteersRabiesISRCTN12693237Crucell Holland BV (The Netherlands)44
进行中（未招募）
1 期
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid TumorsLocally Advanced or Metastatic Solid TumorsNCT06328439Avistone Biotechnology Co., Ltd.40
已完成
1 期
A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaHepatocellular Carcinoma (HCC)NCT02508467Blueprint Medicines Corporation146
招募中
1 期
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid TumorsAdvanced Solid TumorNCT05007782Gilead Sciences416
招募中
1 期
Safety and Efficacy of BA1302 in Patients With Advanced Solid TumorsPancreatic AdenocarcinomaBreast CancerMelanomaNon-Small Cell Lung CancerNCT06596915Shandong Boan Biotechnology Co., Ltd167